Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes

Current Opinion in Investigational Drugs

Volumn 4, Issue 4, 2003, Pages 412-420

  Wiedeman, Paul E ^a   Trevillyan, James M ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Dipeptidyl peptidase IV; Glucagon like peptide 1 (GLP 1); Glucose dependent insulinotropic polypeptide (GIP); Type 2 diabetes

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; AMINOMETHYLISOQUINOLONE DERIVATIVE; ANTIDIABETIC AGENT; CARBAMOYLTRIAZOLE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPROTIN A; DOPAMINE RECEPTOR; FE 999011; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUTAMIC ACID; HEMOGLOBIN A1C; HYDROLASE INHIBITOR; ISOLEUCINE THIAZOLIDIDE; ISOQUINOLINE DERIVATIVE; OXAZOLIDINE DERIVATIVE; PYRAZOLINE DERIVATIVE; PYRROLE DERIVATIVE; PYRROLIDINE DERIVATIVE; PYRROLINE DERIVATIVE; QUINOLONE DERIVATIVE; SULPHOSTIN; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINE PYRROLIDIDE; VILDAGLIPTIN; XANTHINE DERIVATIVE;

ALKYLATION; CHEMICAL MODIFICATION; CLINICAL TRIAL; COMBINATORIAL CHEMISTRY; CONTINUOUS INFUSION; DIABETES MELLITUS; DIET THERAPY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG ISOLATION; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME DEGRADATION; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPERTRIGLYCERIDEMIA; IC 50; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; KINESIOTHERAPY; LONG TERM CARE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRURITUS; REVIEW; RHINOPHARYNGITIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; PROTEASE INHIBITORS; PYRROLIDINES;

EID: 0037869031     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Mojsov S, Weir GC, Habener JF: Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest (1987) 79(2):616-619.
2. Fehmann HC, Habener JF: Insulinotropic hormone glucagon-like peptide-I (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma β TC-1 cells. Endocrinology (1992) 130(1):159-166.
3. Xu G, Stoffers DA, Habener JF, Bonner-Weir S: Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes (1999) 48(12):2270-2276.
4. Zhou J, Wang X, Pineyro MA, Egan JM: Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes (1999) 48(12):2358-2366.
5. Larsson H, Holst JJ, Ahren B: Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand (1997) 160(4):413-422.
6. Schirra J, Katschinski M, Weidmann C, Schafer T, Wank U, Arnold R, Goke B: Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest (1996) 97(1):92-103.
7. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP et al: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature (1996) 379(6560):69-72.
8. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: A parallel-group study. Lancet (2002) 359(9309):824-830.
9. Gutniak MK, Svartberg J, Hellstrom PM, Holst JJ, Adner N, Ahren B: Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes. J Intern Med (2001) 250(1):81-87.
10. Rachman J, Barrow BA, Levy JC, Turner RC: Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia (1997) 40(2):205-211.
11. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med (1992) 326(20):1316-1322.
12. Mentlein R: Dipeptidyl-peptidase IV (CD26) - Role in the inactivation of regulatory peptides. Regul Pept (1999) 85(1):9-24.
13. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ: Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type 2 diabetic patients and in healthy subjects. Diabetes (1995) 44(9):1126-1131.
14. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA (2000) 97(12):6874-6879. Validation that GLP-1 is an endogenous substrate for DPPIV and that lack of DPPIV activity improves glucose tolerance in otherwise healthy mice.
15. Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Yoshikawa S, Asano O, Tanaka I: Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun (2001) 284(2):501-506.
16. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes (1998) 47(8):1253-1258.
17. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia (1999) 42(11):1324-1331.
18. Ahren B, Holst JJ, Martensson H, Balkan B: Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol (2000) 404(1-2):239-245.
19. Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Tanaka I: Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metabolism (2003) 52(1):81-86.
20. Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA: Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: A euglycemic-hyperinsulinemic clamp study. Diabetes (2002) 51(9):2677-2683.
21. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, McIntosh CH, Pederson RA: Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes (2002) 51(4):943-950.
22. Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML: Chronic inhibition of circulating dipeptidyl peptidase IV by FE-999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes (2002) 51(5):1461-1469. Evidence is presented that DPPIV inhibition may delay progression to diabetes.
23. Reimer MK, Holst JJ, Ahren B: Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol (2002) 146(5):717-727.
24. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA: Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes (2003) 52(3):741-750.
25. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S et al: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care (2002) 25(5):869-875. Study demonstrating that DPPIV inhibition improves glucose tolerance in type 2 diabetic individuals and may be an effective approach in the treatment of early stages of the disease.
26. Villhauer EB, Coppola GM, Hughes TE: DPP-IV inhibition and therapeutic potential. In: Annual Reports in Medicinal Chemistry. Doherty AM (Ed), Academic Press, San Diego, CA, USA (2001):191-200. A comprehensive review covering early structural characterization, therapeutic potential and a listing of DPPIV inhibitors.
27. Evans DM: Dipeptidyl peptidase IV inhibitors. IDrugs (2002) 5(6):577-585.
28. Hoffman T, Demuth H-U: Therapeutic strategies exploiting DP IV inhibition: Target disease: Type 2 diabetes. Ectopeptidases (2002):259-278. This paper includes a discussion of DPPIV in type 2 diabetes, the selection of a DPPIV inhibitor and preclinical evaluation. It also includes a listing of compounds in clinical evaluation.
29. Snow RJ, Bachovchin WW: Boronic acid inhibitors of dipeptidyl peptidase IV: A new class of immunosuppressive agents. Adv Med Chem (1995) 3:149-177.
30. Li J, Wilk E, Wilk S: Aminoacylpyrrolidine-2-nitriles: Potent and stable inhibitors of dipeptidyl-peptidase IV (CD26). Arch Biochem Biophys (1995) 323(1):148-154.
31. Hughes TE, Mone MD, Russell ME, Weldon SC, Villhauer EB: (1-[[[2-(5-Cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry (1999) 38(36):11597-11603.
32. Stoeckel-Maschek A, Stiebitz B, Born I, Faust J, Moegelin W, Neubert K: Potent inhibitors of dipeptidyl peptidase IV and their mechanisms of inhibition. In: Cellular Peptidases in Immune Functions and Diseases. Langner J, Ansorge S (Eds), Kluwer Academic/Plenum Publishers, New York, NY, USA (2000) 2:117-123.
33. Borloo M, Augustyns K, Belyaev A, De Meester I, Lambeir A-M, Goossens F, Bollaert W, Rajan P, Scharpe S, Haemers A: Synthesis and evaluation of azaproline peptides as potential inhibitors of dipeptidyl peptidase IV and prolyl oligopeptidase. Letters Peptide Science (1995) 2:198-202.
34. Piron J, Tourwe D: Stereoselective synthesis of transition state analog inhibitors of DPP-IV using 2-substituted thiazoles. In: Peptides. The Wave of the Future. Lebl M, Houghten RA (Eds), American Peptide Society (2001):150-151.
35. Zhao K, Lim DS, Funaki T, Welch JT: Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1-fluoro-propylidene)-cyclopentanecarbonitrile, a fluoroolefin containing peptidomimetic. Bioorg Med Chem (2003) 11(2):207-215.
36. Villhauer EB, Brinkman JA, Naderi GB, Dunning BE, Mangold BL, Mone MD, Russell ME, Weldon SC, Hughes TE: 1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile : A potent, selective, and orally bioavailable dipeptidylpeptidase IV inhibitor with antihyperglycemic properties. J Med Chem (2002) 45(12):2362-2365.
37. Brinkman JA, Villhauer EB, Naderi GB, Hughes TE, Mone M, Russell ME, Weldon SC: Design and Synthesis of N-substituted Glycyl 2-Cyanopyrrolidines as a New Class of DPP-IV Inhibitors. 222nd American Chemical Society National Meeting, Chicago, IL, USA. (2002):MEDI-039.
38. Willand N, Joossens J, Gesquière J-C, Tartar AL, Evans DM, Roe MB: Solid and solution phase syntheses of the 2-cyanopyrrolidide DPP-IV inhibitor NVP-DPP728. Tetrahedron (2002) 58(28):5741-5746.
39. Hughes TE, Russell ME, Bolognese L, Li X, Burkey BF, Wang PR, Villahauer EB: NVP-LAF237, a highly selective and long-acting dipeptidyl peptidase IV inhibitor. Diabetes (2002) 51(Suppl 2):Abs 272-OR.
40. Coppola GM, Zhang YL, Schuster HF, Russell ME, Hughes TE: 1-Aminomethylisoquinoline-4-carboxylates as novel dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett (2000) 10(14):1555-1558.
41. Kanstrup A, Branner S, Carr RD, Christiansen LB, Elm T, Ribel U: A Structurally Novel Dipeptidyl Peptidase IV Inhibitor: 7-Benzyl-1,3-Dimethyl-8-Piperazinoxanthine. 28th National Medicinal Chemistry Symposium, San Diego, CA, USA (2002):Abs 72.
42. Akiyama T, Abe M, Harada S, Kojima F, Sawa R, Takahashi Y, Naganawa H, Homma Y, Hamada M, Yamaguchi A, Aoyagi T et al: Sulphostin, a potent inhibitor for dipeptidyl peptidase IV from Streptomyces sp MK251-43F3. J Antibiot (2001) 54(9):744-746.
43. Brandt W: Development of a tertiary-structure model of the C-terminal domain of DPP-IV. In: Cellular Peptidases in Immune Functions and Diseases. Langner J, Ansorge S (Eds), Kluwer Academic/Plenum Publishers, New York, NY, USA (2000) 2:97-101.
44. Reva B, Finkelstein A, Topiol S: Threading with chemostructural restrictions method for predicting fold and functionally significant residues: Application to dipeptidylpeptidase IV (DPP-IV). Proteins (2002) 47(2):180-193.
45. Abbott CA, McCaughan GW, Levy MT, Church WB, Gorrell MD: Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted β propeller domain. Eur J Biochem (1999) 266(3):798-810.
46. Gorrell MD, Gysbers V, McCaughan GW: CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol (2002) 54(3):249-264. A review focused on the structure and function of DPPIV and implications of its ligand binding activity on T-cell proliferation and T-cell co-stimulatory activity of CD26.
47. Rasmussen HB, Branner S, Wiberg FC, Wagtmann N: Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol (2003) 10(1):19-25. First X-ray structure complete with bound inhibitor is reported.
48. Hiramatsu H, Kyono K, Shima H, Fukushima C, Sugiyama S, Inaka K, Yamamoto A, Shimizu R: Crystallization and preliminary X-ray study of human dipeptidyl peptidase IV (DPPIV). Acta Crystallogr Sect D Biol Crystallogr (2003) D59(Pt 3):595-596.
49. Abbott CA, McCaughan GW, Gorrell MD: Two highly conserved glutamic acid residues in the predicted β propeller domain of dipeptidyl peptidase IV are required for its enzyme activity. FEBS Lett (1999) 458(3):278-284.
50. Larsen J, Hylleberg B, Ng K, Damsbo P: Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care (2001) 24(8):1416-1421.
51. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes (2001) 50(3):609-613.
52. Kjems LL, Holst JJ, Volund A, Madsbad S: The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes (2003) 52(2):380-386.
53. Ferring BV (Jenkins PD, Jones DM, Szelke M): DP-IV-Serine Protease Inhibitors. WO-95015309 (1995).
54. Probiodrug AG (Demuth HU, Hoffmann T, Manhart S, Hoffmann M, Heins J): Peptide Structures Useful for Competitive Modulation of Dipeptidyl Peptidase IV Catalysts. WO-03002593 (2003).
55. Bristol-Myers Squibb Co (Sulsky RB, Robl JA): 2,1-Oxazoline and 1,2-Pyrazoline-based Inhibitors of Dipeptidyl Peptidase IV and Method. WO-02083128 (2002).
56. Novo Nordisk A/S (Kanstrup A, Lundbeck JM, Christiansen LB): N-substituted 2-Cyanopyroles and -Pyrrolines Which are Inhibitors of the Enzyme DPP-IV. WO-01055105 (2001).
57. Taisho Pharmaceutical Co Ltd (Fukushima H, Hiratate A, Takahashi M, Kameo K): Cyanopyrrolidine Derivatives. WO-02038541 (2001).
58. Bristol-Myers Squibb Co (Robl JA, Sulsky RB, Augeri DJ, Magnin DR, Hamann LG, Betebenner DA): Cyclopropyl-fused Pyrrolidine-based Inhibitors of Dipeptidyl Peptidase IV and Method. WO-01068603 (2001).
59. Ferring BV (Evans DM, Pitt GRW): Inhibitors of Dipeptidyl Peptidase IV. WO-01081304 (2001).
60. Ferring BV (Evans DM, Pitt GRW): Inhibitors of Dipeptidyl Peptidase IV. WO-01081337 (2001).
61. Ferring BV (Pitt GRW, Evans DM): 3-Fluoro-pyrrolidines as Antidiabetic Agents. WO-03000250 (2003).
62. SmithKline Beecham Corporation (Haffner CD, McDougald DL, Randhawa AS, Reister SM, Deaton DN, Lenhard JM): Pyrrolidines as Dipeptidyl Peptidase Inhibitors. WO-03002530 (2003).
63. SmithKline Beecham Corporation (Haffner CD, McDougald DL, Randhawa AS, Reister SM, Lenhard JM): Fluoropyrrolidines as Dipeptidyl Peptidase Inhibitors. WO-03002531 (2003).
64. Mitsubishi Well Pharma (Kitashima H, Yoshida T, Sonda S, Akaboshi F, Hayashi Y:) Preparation of N-(α-aminoacyl)-2-cyanopyrrolidine derivatives as inhibitors of dipeptidyl peptidase IV (DPP-IV) for drugs. JP-2002265439 (2002).
65. Les Laboratories Servier (De Nanteuil G, Portevin B, Benoist A, Levens N, Nosjean O, Husson-Robert B:) Sulfonyl derivatives of amino acids and their use as inhibitors of dipeptidyl-peptidase IV (DPP IV). EP-01245568 (2002).
66. Merck & Co Inc (Ashton, WT, Caldwell CG, Ok H, Parmee ER, Weber AE): Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes. WO-02076450 (2002).
67. Merck & Co Inc (Edmondson SD, Parmee E, Weber AE, Xu J): Dipeptidyl peptidase inhibitors for the treatment of diabetes. WO-0000180 (2003).
68. Merck & Co Inc (Brockunier L, Parmee E, Weber AE:): Dipeptidyl peptidase inhibitors for the treatment of diabetes. WO-03000181 (2003).
69. Merck & Co Inc (Edmondson SD, Fisher MH, Kim D, Maccoss M, Parmee ER, Weber AE, Xu J:) β-Amino tetrahydroimidazo(1,2-a)pyrazines and tetrahydrotriazolo(4,3-a)pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes. WO-03004498 (2003).
70. Novartis AG (Damon R): Tetrahydroisoquinoline 3-carboxamide derivatives. US-06172081 (2001).
71. Welfide Corporation (Kitajima H, Sakashita H, Akahoshi F, Hayashi Y): Proline derivatives and use thereof as drugs. WO: 02014271 (2002).
72. Novartis AG (Villhauer EB): N-(Substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV. US-06011155 (2000).
73. Novartis AG (Villhauer EB): N-Substituted 2-cyanopyrrolidines. WO-09819998 (1998).
74. Novartis AG (Villhauer EB): N-Substituted 2-Cyanopyrrolidines. WO-00034241 (2000).
75. Novartis AG (Villhauer EB): N-(Substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV. US-06107317 (2000).
76. Novartis AG (Villhauer EB): N-(Substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV. US-06110949 (2000).
77. Novartis AG (Villhauer EB): N-(Substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV. US-06432969 (2002).
78. Novartis (Villhauer EB): Organic compounds. WO-01096295 (2001).
79. Tanabe Seiyaku Co Ltd (Yasuda K, Morimoto H, Kawanami S, Hikota M, Matsumoto T, Arakawa K): Nitrogenous five-membered ring compounds. WO-02030890 (2002).
80. Tanabe Seiyaku Co Ltd (Yasuda K, Morimoto H, Kawanami S, Hikota M, Matsumoto T, Arakawa K): Aliphatic nitrogenous five-membered ring compounds. WO-02030891 (2002).
81. Kyowa Hakko Kogyo Co Ltd (Matsuno K, Ueno K, Iwata Y, Matsumoto Y, Nakanishi S, Takasaki K, Kusaka H, Nomoto Y, Ogawa A): Dipeptidyl peptidase IV inhibitor. WO-02051836 (2002).
82. SmithKline Beecham Corporation (Haffner CD, McDougald DL, Lenhard JM): Fluoropyrrolidines as dipeptidyl peptidase inhibitors. WO-03002553 (2003).
83. Takeda Chemical Industries Ltd (Oi S, Ikedou K, Takeuchi K, Ogino M, Banno Y, Tawada H, Yamane T): Fused heterocyclic compounds. WO-02062764 (2002).
84. Novo Nordisk A/S (Kanstrup AB, Christiansen LB, Lundbeck JM, Sams CK, Kristiansen M): Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV. WO-02002560 (2002).
85. Boehringer Ingelheim Pharma KG (Himmelsbach F, Mark M, Eckhardt M, Langkopf E, Maier R, Lotz R): Xanthine derivative, production and use thereof as a medicament. WO-02068420 (2002).
86. Novo Nordisk A/S (Kanstrup AB, Sams CK, Lundbeck JM, Christiansen LB, Kristiansen M): DPP-IV-inhibiting purine derivatives for the treatment of diabetes. WO-03004496 (2003).
87. Eisai Co Ltd (Yasuda N, Tsuchiura-shi I, Nagakura T, Ushiki-shi I:): Pharmaceutical use of N-carbamoylazole derivatives. EP-01258480 (2002).
88. Probiodrug (Demuth H-U, Hoffmann T, Schlenzig D, Manhart S): Prodrugs of dipeptidyl peptidase IV inhibitors. WO-09967278 (1999).
89. Ferring BV (Evans DM): Novel antidiabetic agents. WO-00140180 (2001).